Vanguard Fiduciary Trust’s Lucid Diagnostics LUCD Stock Holding History
Bought
Maintained
Sold
Other funds holding LUCD
TSC
MCM
Vanguard Fiduciary Trust's LUCD Position: Q2 2026 in Review
Vanguard Fiduciary Trust increased its Lucid Diagnostics (LUCD) stake by 71% in Q2 2026, buying an estimated $479K and bringing the position to 1,068,109 shares worth $1.14M. The position accounts for ﹤0.01% of the portfolio, ranked #2968.
Vanguard Fiduciary Trust first reported a position in LUCD in Q1 2026 and has held it in 2 quarters since. 114 funds tracked by Wall St. Rank hold LUCD as of Q2 2026.
- Vanguard Fiduciary Trust held 1,068,109 shares of Lucid Diagnostics worth $1.14M as of Q2 2026.
- Vanguard Fiduciary Trust bought 444,552 Lucid Diagnostics shares in Q2 2026, an estimated $479K.
- Lucid Diagnostics made up ﹤0.01% of Vanguard Fiduciary Trust's portfolio in Q2 2026, its #2968 holding.
- Vanguard Fiduciary Trust first reported a position in Lucid Diagnostics in Q1 2026 and has held it in 2 quarters since.
- 114 funds tracked by Wall St. Rank held Lucid Diagnostics as of Q2 2026.
Based on Vanguard Fiduciary Trust's 13F filing for Q2 2026, filed 13 Aug 2026.